Folker Schneller

Ismaninger Str. 22
Munich, BY 81675, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 10 publications

Serum metabolomic signatures predict clinical outcomes in advanced non-small cell lung cancer treated with pembrolizumab plus platinum-based chemotherapy.

Serum metabolomic signatures predict clinical outcomes in advanced non-small cell lung cancer treated with pembrolizumab plus platinum-based chemotherapy.

Journal: Frontiers in immunology

Published: December 18, 2025

Metabolic phenotype and gender may predict treatment outcomes of atezolizumab in extensive-stage small cell lung cancer.

Metabolic phenotype and gender may predict treatment outcomes of atezolizumab in extensive-stage small cell lung cancer.

Journal: Translational lung cancer research

Published: April 15, 2025

Comparison of survival and progression after focal- or whole brain radiotherapy in patients with primary CNS lymphoma - Results from a large multicenter analysis of the German Society of Radiation Oncology's Neuro-Radio-Oncology Working Group (DEGRO AG-NRO).

Comparison of survival and progression after focal- or whole brain radiotherapy in patients with primary CNS lymphoma - Results from a large multicenter analysis of the German Society of Radiation Oncology's Neuro-Radio-Oncology Working Group (DEGRO AG-NRO).

Journal: Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology

Published: November 14, 2024

Predicting resistance and pseudoprogression: are minimalistic immunoediting mathematical models capable of forecasting checkpoint inhibitor treatment outcomes in lung cancer?

Predicting resistance and pseudoprogression: are minimalistic immunoediting mathematical models capable of forecasting checkpoint inhibitor treatment outcomes in lung cancer?

Journal: Mathematical biosciences

Published: March 21, 2024

Molecular subgroups of T-cell acute lymphoblastic leukemia in adults treated according to pediatric-based GMALL protocols.

Molecular subgroups of T-cell acute lymphoblastic leukemia in adults treated according to pediatric-based GMALL protocols.

Journal: Leukemia

Published: October 18, 2023

Developmental trajectories and cooperating genomic events define molecular subtypes of BCR::ABL1-positive ALL.

Developmental trajectories and cooperating genomic events define molecular subtypes of BCR::ABL1-positive ALL.

Journal: Blood

Published: July 05, 2023

A randomized, controlled trial evaluating the efficacy and safety of BTH1677 in combination with bevacizumab, carboplatin, and paclitaxel in first-line treatment of advanced non-small cell lung cancer.

A randomized, controlled trial evaluating the efficacy and safety of BTH1677 in combination with bevacizumab, carboplatin, and paclitaxel in first-line treatment of advanced non-small cell lung cancer.

Journal: Journal for immunotherapy of cancer

Published: October 19, 2017

A phase I/IIa study of the mRNA-based cancer immunotherapy CV9201 in patients with stage IIIB/IV non-small cell lung cancer.

A phase I/IIa study of the mRNA-based cancer immunotherapy CV9201 in patients with stage IIIB/IV non-small cell lung cancer.

Journal: Cancer immunology, immunotherapy : CII

Published: July 13, 2017

A randomized, open-label, multicenter, phase II study evaluating the efficacy and safety of BTH1677 (1,3-1,6 beta glucan; Imprime PGG) in combination with cetuximab and chemotherapy in patients with advanced non-small cell lung cancer.

A randomized, open-label, multicenter, phase II study evaluating the efficacy and safety of BTH1677 (1,3-1,6 beta glucan; Imprime PGG) in combination with cetuximab and chemotherapy in patients with advanced non-small cell lung cancer.

Journal: Investigational new drugs

Published: February 16, 2017

A randomized phase II study of pemetrexed in combination with cisplatin or carboplatin as first-line therapy for patients with locally advanced or metastatic non-small-cell lung cancer.

A randomized phase II study of pemetrexed in combination with cisplatin or carboplatin as first-line therapy for patients with locally advanced or metastatic non-small-cell lung cancer.

Journal: Clinical lung cancer

Published: June 26, 2012

Showing 1-10 of 10

Last Updated: 09/26/2026